格隆汇1月26日｜恒瑞医药公告，公司收到国家药品监督管理局核准签发关于SHR-1049注射液的《药物 临床试验批准通知书》，将于近期开展临床试验。SHR-1049注射液是公司自主研发的创新型抗肿瘤药 物，拟用于治疗晚期实体瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-1049注射 液相关项目累计研发投入约为2,600万元(未经审计)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发关于 SHR-1049 注射液的《药物临 床试验批准通知书》，将于近期开展临床试验。现将相关情况公 ...

Core Viewpoint - The report highlights the current AH premium rates of various stocks, indicating significant disparities between H-shares and A-shares, with some stocks showing extremely high premiums while others exhibit negative premiums [1][2]. Group 1: Top AH Premium Rates - Northeast Electric (00042) leads with an AH premium rate of 815.25%, followed by Zhejiang Shibao (01057) at 363.71% and Beijing Jingcheng Machinery Electric (00187) at 272.95% [1][2]. - The top ten stocks with the highest AH premium rates include Sinopec Oilfield Service (01033) at 270.11% and Hongye Futures (03678) at 263.50% [2]. Group 2: Lowest AH Premium Rates - The stocks with the lowest AH premium rates include CATL (03750) at -11.21%, followed by Hengrui Medicine (01276) at -2.51% and China Merchants Bank (03968) at -1.68% [1][2]. - Other notable stocks with low premiums include WuXi AppTec (02359) at 2.25% and Midea Group (00300) at 7.52% [2]. Group 3: Premium Deviation Values - The stocks with the highest deviation values include Goldwind Technology (02208) at 30.93%, followed by Andeli Juice (02218) at 22.80% and CanSino Biologics (06185) at 21.10% [1][2]. - Conversely, the stocks with the lowest deviation values include Yangtze Optical Fibre and Cable (06869) at -26.96%, Nanhua Futures (02691) at -26.55%, and Northeast Electric (00042) at -26.34% [1][3].

Group 1 - The company is steadily advancing its internationalization strategy, particularly in the European Union region [1] - The company has a diverse approach to its drug export sales business in the EU [1] - Currently, the revenue from the EU business accounts for a small proportion of the company's overall operating income [1]

Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 815.25%, Zhejiang Shibao (01057) at 353.47%, and Sinopec Oilfield Service (01033) at 275.00% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -11.83%, China Merchants Bank (03968) at -3.19%, and Heng Rui Medicine (01276) at -3.03% [1][2] - The companies with the highest deviation values are Jinyu Group (02009) at 26.31%, Sanhua Intelligent Control (02050) at 19.65%, and Goldwind Technology (02208) at 18.92% [1][2] Group 2 - The top ten AH stocks by premium rate include companies like Northeast Electric (00042), Zhejiang Shibao (01057), and Sinopec Oilfield Service (01033) [2] - The bottom ten AH stocks by premium rate include companies like CATL (03750), China Merchants Bank (03968), and Heng Rui Medicine (01276) [2] - The top ten AH stocks by deviation value include Jinyu Group (02009), Sanhua Intelligent Control (02050), and Goldwind Technology (02208) [3]

Core Insights - The article highlights the premium rates of AH shares, with Northeast Electric (00042), Zhejiang Shibao (01057), and Junda Co., Ltd. (02865) leading the list with premium rates of 831.03%, 367.07%, and 320.34% respectively [1] - Conversely, CATL (03750), Heng Rui Medicine (01276), and China Merchants Bank (03968) have the lowest premium rates at -11.41%, -3.46%, and -1.49% respectively [1] Premium Rate Rankings - The top ten AH shares by premium rate include: - Northeast Electric (00042): H-share at 0.290 HKD, A-share at 2.25 CNY, premium rate of 831.03%, deviation value of -17.64% [1] - Zhejiang Shibao (01057): H-share at 5.770 HKD, A-share at 22.5 CNY, premium rate of 367.07%, deviation value of -14.31% [1] - Junda Co., Ltd. (02865): H-share at 25.760 HKD, A-share at 90.4 CNY, premium rate of 320.34%, deviation value of 77.25% [1] - The bottom ten AH shares by premium rate include: - CATL (03750): H-share at 472.200 HKD, A-share at 349.24 CNY, premium rate of -11.41%, deviation value of 0.38% [1] - Heng Rui Medicine (01276): H-share at 73.750 HKD, A-share at 59.44 CNY, premium rate of -3.46%, deviation value of -3.66% [1] - China Merchants Bank (03968): H-share at 46.300 HKD, A-share at 38.08 CNY, premium rate of -1.49%, deviation value of 0.47% [1] Deviation Value Rankings - The top three AH shares by deviation value are: - Longqi Technology (09611): H-share at 32.100 HKD, A-share at 48.16 CNY, premium rate of 79.72%, deviation value of 79.72% [1] - Junda Co., Ltd. (02865): H-share at 25.760 HKD, A-share at 90.4 CNY, premium rate of 320.34%, deviation value of 77.25% [1] - Goldwind Technology (02208): H-share at 15.400 HKD, A-share at 26.89 CNY, premium rate of 109.16%, deviation value of 20.91% [1] - The bottom three AH shares by deviation value are: - Yangtze Optical Fibre and Cable (06869): H-share at 52.050 HKD, A-share at 109.7 CNY, premium rate of 152.45%, deviation value of -18.19% [2] - Northeast Electric (00042): H-share at 0.290 HKD, A-share at 2.25 CNY, premium rate of 831.03%, deviation value of -17.64% [2] - Chenming Paper (01812): H-share at 0.820 HKD, A-share at 2.19 CNY, premium rate of 219.51%, deviation value of -15.59% [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SHR-7787 injection and Adebeli monoclonal antibody injection, indicating progress in its oncology pipeline [1][2] Group 1: SHR-7787 Injection - SHR-7787 injection is a Class 1 therapeutic biological product designed to activate T cells to target and kill tumor cells [1] - The total research and development investment for SHR-7787 injection has reached approximately 54.1 million yuan (unaudited) [1] Group 2: Adebeli Monoclonal Antibody Injection - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody that reactivates the immune system's anti-tumor activity by blocking the PD-1/PD-L1 pathway [2] - The product was approved for market in 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [2] - Global sales of similar products Atezolizumab, Avelumab, and Durvalumab are projected to total approximately 9.648 billion USD in 2024 [2] - The total research and development investment for Adebeli monoclonal antibody injection has reached approximately 1.101 billion yuan (unaudited) [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SHR-7787 injection and Adebali monoclonal antibody injection, indicating progress in its oncology pipeline [1][2] Group 1: SHR-7787 Injection - SHR-7787 injection is a Class 1 therapeutic biological product that activates T cells to target and kill tumor cells [1] - The total R&D investment for SHR-7787 injection has reached approximately 54.1 million yuan (unaudited) [1] Group 2: Adebali Monoclonal Antibody Injection - Adebali monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody that reactivates the immune system's anti-tumor activity by blocking the PD-1/PD-L1 pathway [2] - The injection was approved for market in 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [2] - The total R&D investment for Adebali monoclonal antibody injection has reached approximately 1.101 billion yuan (unaudited) [2] - Global sales of similar products Atezolizumab, Avelumab, and Durvalumab are projected to total approximately 9.648 billion USD in 2024 [2]

Group 1 - Company subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd. received approval from the National Medical Products Administration for clinical trials of SHR-7787 injection and Adebeli monoclonal antibody injection [1] - SHR-7787 injection is a Class 1 therapeutic biological product that activates T cells to target and kill tumor cells, with a cumulative R&D investment of approximately 54.1 million yuan (unaudited) [1] Group 2 - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody that blocks the PD-1/PD-L1 pathway to reactivate the immune system's anti-tumor activity, approved for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [2] - The global sales of similar products Atezolizumab, Avelumab, and Durvalumab are projected to reach approximately 9.648 billion USD in 2024, with Atezolizumab and Durvalumab already approved for sale in China [2] - The cumulative R&D investment for Adebeli monoclonal antibody injection is approximately 1.101 billion yuan (unaudited) [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年1月21日 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-01 ...